Reaction
Immune-Mediated Myocarditis reporting signals
As of the last recalculation, Immune-Mediated Myocarditis appears in 1,519 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 184.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 734 | 184.0 | 185.3 |
| Ipilimumab | 280 | 108.7 | 109.5 |
| Nivolumab | 497 | 104.2 | 104.8 |
| Durvalumab | 93 | 66.7 | 67.0 |
| Pemetrexed Disodium | 73 | 27.5 | 27.6 |
| Pemetrexed | 40 | 26.2 | 26.3 |
| Lenvatinib | 59 | 25.6 | 25.6 |
| Axitinib | 34 | 24.4 | 24.5 |
| Atezolizumab | 62 | 22.8 | 22.8 |
| Carboplatin | 186 | 22.7 | 22.8 |
| Paclitaxel (Aibumin-Bound) | 121 | 21.8 | 21.9 |
| Paclitaxel | 128 | 19.2 | 19.3 |
| Doxorubicin | 74 | 11.9 | 11.9 |
| Cisplatin | 65 | 11.9 | 11.9 |
| Febuxostat Tablets 40 Mg | 8 | 10.8 | 10.8 |
| Febuxostat Tablets 80 Mg | 8 | 10.8 | 10.8 |
| Doxorubicin Hydrochloride | 24 | 10.2 | 10.2 |
| Gemcitabine Hydrochloride | 34 | 9.0 | 9.0 |
| Oxaliplatin | 44 | 8.3 | 8.3 |
| Icosapent Ethyl | 5 | 8.1 | 8.1 |
| Fluorouracil Cream, 0.5% | 43 | 7.9 | 7.9 |
| Fluorouracil | 43 | 7.8 | 7.8 |
| Cetuximab | 14 | 6.2 | 6.2 |
| Cabozantinib | 21 | 6.1 | 6.1 |
| Regorafenib | 5 | 5.9 | 5.9 |
| Gemcitabine | 15 | 5.3 | 5.3 |
| Abiraterone | 5 | 5.0 | 5.0 |